Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis - Takeaways - MDSpire

Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis

  • By

  • Ke-qian Chen

  • Yang Chen

  • Jing-Fu Peng

  • Yi Huang

  • Xiang Liu

  • June 17, 2026

  • 0 min

Share

  • 1

    The study analyzed 42 case reports of pembrolizumab-induced immune-related hepatitis to improve clinical management and treatment safety.

  • 2

    Patients included 27 males and 14 females, with an average age of 64.2 years, indicating a higher prevalence among older males.

  • 3

    Clinical manifestations of immune-related hepatitis included liver toxicity, neurological symptoms, skin reactions, and digestive symptoms.

  • 4

    Corticosteroids were the primary treatment for immune-related hepatitis, with onset times varying from 2 to 630 days after pembrolizumab initiation.

  • 5

    The study emphasizes the need for thorough liver function evaluation and regular monitoring during pembrolizumab treatment.

Original Source(s)

Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis

  • by Ke-qian Chen, Yang Chen, Jing-Fu Peng, Yi Huang, Xiang Liu

  • June 17, 2026

Related Content

Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

Revisiting gastric cancer disparities in Asian American subgroups: insights from the SEER database